GLP-1 Therapies Newsletter
Issue #29March 23, 20267 studies

Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%

GLP-1 drugs like Ozempic and Wegovy are everywhere—but new research reveals a critical safety issue that could affect millions of users heading into routine medical procedures.

🚨 Skip One Dose, Avoid Major Complications

  • 60 patients on GLP-1 drugs were randomly assigned to either continue their medication or skip one dose before upper endoscopy procedures

  • Patients who continued their medication had 25% risk of dangerous stomach contents during the procedure, compared to just 3.1% who skipped one dose

  • The study was stopped early because the risk difference was so dramatic—21.9 percentage points higher in the continue group

Why it matters: Retained stomach contents during sedated procedures can lead to aspiration, requiring emergency intubation or extended hospital stays. This is the first randomized trial showing that simply holding one dose dramatically reduces this risk.

🥈 Top 2% journal 🔗 JAMA internal medicine 🗓️ Mar 16

Key Findings

💊 Hybrid Drug Beats Appetite for 63 Hours Straight

  • Scientists created a combination GLP-1/apelin drug that suppressed appetite in mice for 42-63 hours (compared to standard GLP-1 drugs that last ~24 hours)

  • The hybrid also enhanced insulin secretion and protected pancreatic cells better than either drug alone

  • Effects required both receptors to work—blocking either one eliminated the benefits

💡 Combining two hormone pathways may create more powerful, longer-lasting obesity treatments than current single-target drugs.

🫀 Heart Protection Beyond Blood Sugar

  • Semaglutide protected rat hearts from coronary microembolization (tiny clots that damage heart muscle during procedures)

  • The drug reduced heart cell death and inflammation by blocking a specific inflammatory pathway (HMGB1/RAGE/NF-κB)

  • Protection occurred even when the drug was given before the heart injury, suggesting preventive potential

💡 GLP-1 drugs may protect the heart through direct anti-inflammatory effects, not just weight loss and blood sugar control.
Top 50% journal 🔗 Journal of geriatric cardiology : JGC 🗓️ Mar 16

📊 Social Factors Block Access to Game-Changing Drugs

  • Analysis of 14.6 million patients found major disparities in who gets prescribed SGLT2 inhibitors and GLP-1 drugs

  • Low-income patients had 27% lower odds of receiving these medications, while Medicaid patients had 30% lower odds than privately insured

  • Black patients had 20% lower odds and Asian patients had 51% lower odds of getting GLP-1 drugs compared to white patients

💡 Despite proven benefits for diabetes and heart disease, access to these breakthrough medications remains heavily influenced by socioeconomic status and race.
🥉 Top 5% journal 🔗 Journal of general internal medicine 🗓️ Mar 16

🔬 New Combo Drug Delivers 7.5% More Weight Loss

  • Cagrisema (a combination of semaglutide plus cagrilintide) produced 7.47% greater weight loss than semaglutide alone in 3,545 patients

  • Side effects were similar between groups, though combination therapy increased injection site reactions and nausea

  • The dual-hormone approach targets both GLP-1 and amylin pathways simultaneously

💡 Combining multiple hormone targets may be the next evolution in obesity treatment, offering significantly better results than current single-drug approaches.

🏥 Kidney Protection: SGLT2 vs GLP-1 in Obesity

  • Among 178 obese Japanese patients with diabetes, SGLT2 inhibitors showed numerically better kidney protection than GLP-1 drugs over one year

  • Annual kidney function decline was smaller with SGLT2 inhibitors (-1.6 vs -2.8 mL/min), though not statistically significant

  • SGLT2 inhibitors also produced greater blood pressure and weight reductions

💡 For obese diabetic patients, SGLT2 inhibitors may offer slight kidney advantages over GLP-1 drugs, possibly through superior blood pressure control.
Top 30% journal 🔗 Clinical and experimental nephrology 🗓️ Mar 16

🗣️ Rural Patients Face 'Cheating' Stigma

  • Interviews with 9 Danish patients revealed social judgment for using semaglutide for weight loss, with community members viewing it as 'an easy way out'

  • Patients worried about weight regain and viewed the medication as temporary rather than permanent

  • Despite benefits like increased energy, fear of long-term side effects created ongoing anxiety

💡 Social stigma around weight-loss medications may affect treatment adherence and mental health, especially in tight-knit rural communities.

Implications

This week's research reveals both the promise and complexity of GLP-1 drugs—from procedural safety concerns requiring dose timing to breakthrough combination therapies delivering superior results. However, social barriers and access disparities may prevent many patients from benefiting from these advances.

Studies in this issue

Primary sources used for this newsletter.

  1. Comparing Stopping or Continuing GLP-1/GIP Drugs Before Upper Endoscopy
    main storyJAMA internal medicine2026-03-16PMID 41837981
  2. Combined GLP-1 and Apelin Peptides Suppress Appetite and Improve Insulin Release, Beta-Cell Health, and Blood Sugar Control
    key findingDiabetes, obesity & metabolism2026-03-16PMID 41834752
  3. Semaglutide reduces heart injury from small artery blockages by lowering cell death and inflammation through the HMGB1/RAGE/NF-κB p65 pathway
    key findingJournal of geriatric cardiology : JGC2026-03-16PMID 41835369
  4. Kidney health in Japanese people with type 2 diabetes and obesity: comparing two diabetes medicines
    key findingClinical and experimental nephrology2026-03-16PMID 41838277
  5. How Social Factors Relate to Use of SGLT2 Inhibitors and GLP1 Receptor Agonists
    key findingJournal of general internal medicine2026-03-16PMID 41838266
  6. Effectiveness and Safety of Cagrilintide and Cagrisema Compared to Semaglutide for Weight Loss
    key findingDiabetes, obesity & metabolism2026-03-16PMID 41834765
  7. Experiences of Using Semaglutide for Weight Loss in a Rural Area of Denmark
    key findingScandinavian journal of primary health care2026-03-16PMID 41838446

Continue reading

All GLP-1 Therapies issues